Drug Trial Radar · NCT05157945
ALTO-300 in Depression (ALTO-300-004)
Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Feb 3, 2022
Primary completion
Apr 26, 2023
Study completion May 5, 2023
Sponsor
- Lead sponsor
- Alto NeuroscienceIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
Conditions
- Major Depressive Disorder
Interventions
ALTO-300 PO TabletDrug
One tablet daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- To understand the relationship between baseline biology and change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-300Time frame: Measured 6 times over 8 weeks
- To understand the relationship between baseline biology and change in the Clinical Global Impression scale - Severity (CGI-S) with ALTO-300Time frame: Measured 6 times over 8 weeks
- Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-300Time frame: From the signing of the ICF until the follow-up visit (up to 12 weeks)
- Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-300Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)]
- Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-300Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)]
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Cerebral - Atlanta
Atlanta, Georgia
Site 171
Jackson, Mississippi
Cerebral - New York City
New York, New York
Cerebral - Dallas
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.